Tristan Tham1, Michael Wotman2, Ansley Roche2, Dennis Kraus2, Peter Costantino2. 1. Department of Otolaryngology - Head and Neck Surgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, United States of America. Electronic address: ttham@northwell.edu. 2. Department of Otolaryngology - Head and Neck Surgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, United States of America.
Abstract
BACKGROUND: Since most HPV-associated disease occurs in the tonsillar-related areas (TRA) - palatine and lingual tonsils, the effect of HPV on survival in non-tonsillar oropharyngeal subsites (nTRA) is not well established. The objective of this study was to use a large population-based cohort to investigate the survival impact of HPV in nTRA subsites versus TRA subsites. METHODS: This SEER database study was conducted by stratifying the HPV-positive oropharyngeal cancer cohort into two primary groups, TRA and nTRA. RESULTS: HPV-positive squamous cell cancer was significantly more common in TRAs (73%) compared to nTRAs (31.2%, p < 0.001). After controlling for age, treatment, stage, race, and income, patients with HPV-positive disease in nTRAs had a worse cause-specific survival (CSS) than individuals with HPV-positive disease in TRAs (HR = 2.16, 95% CI 1.20-3.86, p = 0.01). CONCLUSION: Patients with HPV-positive OPSCC in nTRAs had poorer survival outcomes compared to patients with HPV-positive OPSCC in TRAs.
BACKGROUND: Since most HPV-associated disease occurs in the tonsillar-related areas (TRA) - palatine and lingual tonsils, the effect of HPV on survival in non-tonsillar oropharyngeal subsites (nTRA) is not well established. The objective of this study was to use a large population-based cohort to investigate the survival impact of HPV in nTRA subsites versus TRA subsites. METHODS: This SEER database study was conducted by stratifying the HPV-positive oropharyngeal cancer cohort into two primary groups, TRA and nTRA. RESULTS:HPV-positive squamous cell cancer was significantly more common in TRAs (73%) compared to nTRAs (31.2%, p < 0.001). After controlling for age, treatment, stage, race, and income, patients with HPV-positive disease in nTRAs had a worse cause-specific survival (CSS) than individuals with HPV-positive disease in TRAs (HR = 2.16, 95% CI 1.20-3.86, p = 0.01). CONCLUSION:Patients with HPV-positive OPSCC in nTRAs had poorer survival outcomes compared to patients with HPV-positive OPSCC in TRAs.
Authors: Mark Zupancic; Linnea Haeggblom; David Landin; Linda Marklund; Tina Dalianis; Anders Näsman Journal: Oncol Lett Date: 2021-02-10 Impact factor: 2.967
Authors: Derek D Kao; Rocco M Ferrandino; Deborah C Marshall; Tinaye Mutetwa; Brett Miles; Joshua M Bauml; Keith M Sigel Journal: Int J Otolaryngol Date: 2022-05-02
Authors: Malin Wendt; Lalle Hammarstedt-Nordenvall; Mark Zupancic; Signe Friesland; David Landin; Eva Munck-Wikland; Tina Dalianis; Anders Näsman; Linda Marklund Journal: Cancers (Basel) Date: 2021-05-23 Impact factor: 6.639
Authors: Anders Näsman; Stefan Holzhauser; Ourania N Kostopoulou; Mark Zupancic; Andreas Ährlund-Richter; Juan Du; Tina Dalianis Journal: Viruses Date: 2021-05-14 Impact factor: 5.048